Yu. A. Yurshev
Yu. A. Yurshev has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- A. O. Prosvetov
Evdokimov Moscow State Medical and Dental University, Russian Ministry of Health, Moscow, Russia
1 shared publication - Boris Dmitrievich Tsygankov
FSBEI HE Russian University of Medicine of the Ministry of Health of the Russian Federation
1 shared publication FSBEI HPE Lomonosov Moscow State University
1 shared publicationFederal State Budgetary Educational Institution of Higher Education «A. I. Yevdokimov Moscow State University of Medicine and Dentistry» of the Ministry of Health of the Russian Federation
1 shared publication- Maksim N. Karagyaur
Medical Research and Education Institute, Lomonosov Moscow State University
1 shared publication - S. R. Rangus
Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
1 shared publication
Latest Publications
- Open Access
- 10 September 2025
- Published by Irkutsk State Medical University in Baikal Medical Journal
- Vol. 4 (3) , 63-73
CURRENT AND PROSPECTIVE APPROACHES TO THE TREATMENT OF TRAUMATIC BRAIN INJURIES
Relevance. Traumatic brain injury remains one of the leading causes of disability and mortality in modern society, while existing treatment methods demonstrate limited effectiveness in preventing the development of secondary brain damage and the occurrence of delayed neurological complications. The lack of drugs with a complex multitarget effect on the main pathogenetic mechanisms of traumatic brain injury necessitates the search for new therapeutic approaches. Aim of the study: to analyze current and promising approaches to the treatment of the consequences of traumatic brain injury, to identify the most promising areas. Methods: a systematic review of the scientific literature, analysis of the results of preclinical and clinical studies on the use of various therapeutic approaches in traumatic brain injury, including standard intensive care, experimental neuroprotective drugs and cell therapy. Results: it was found that the standard existing therapy for the consequences of traumatic brain injury is aimed primarily at maintaining vital functions and controlling intracranial pressure, but does not affect the key mechanisms of secondary brain tissue damage. Most experimental neuroprotective drugs have not demonstrated significant clinical efficacy. One of the most promising approaches to stimulating brain tissue neuroprotection and preventing the development of its secondary damage after traumatic brain injury is therapy with stem cells or their secretion products. The secretome of mesenchymal stromal cells, containing a wide range of biologically active molecules and molecular complexes, has a unique ability to affect a wide range of pathogenetic mechanisms that occur after traumatic brain injury. Recent advances in molecular and cellular biology (in particular, obtaining cell lines with prolonged proliferative potential) open up opportunities for clinical translation of this technology. Conclusion: existing therapy for the consequences of traumatic brain injury has limited effectiveness and does not allow for the prevention of delayed damage to brain tissue. One of the most promising approaches to preventing the development of undesirable consequences of traumatic brain injury is therapy with stem cells or products of their secretion.
- 10 September 2025
- Published by Irkutsk State Medical University in Baikal Medical Journal
- Vol. 4 (3) , 63-73
Open AccessCURRENT AND PROSPECTIVE APPROACHES TO THE TREATMENT OF TRAUMATIC BRAIN INJURIES
Relevance. Traumatic brain injury remains one of the leading causes of disability and mortality in modern society, while existing treatment methods demonstrate limited effectiveness in preventing the development of secondary brain damage and the occurrence of delayed neurological complications. The lack of drugs with a complex multitarget effect on the main pathogenetic mechanisms of traumatic brain injury necessitates the search for new therapeutic approaches. Aim of the study: to analyze current and promising approaches to the treatment of the consequences of traumatic brain injury, to identify the most promising areas. Methods: a systematic review of the scientific literature, analysis of the results of preclinical and clinical studies on the use of various therapeutic approaches in traumatic brain injury, including standard intensive care, experimental neuroprotective drugs and cell therapy. Results: it was found that the standard existing therapy for the consequences of traumatic brain injury is aimed primarily at maintaining vital functions and controlling intracranial pressure, but does not affect the key mechanisms of secondary brain tissue damage. Most experimental neuroprotective drugs have not demonstrated significant clinical efficacy. One of the most promising approaches to stimulating brain tissue neuroprotection and preventing the development of its secondary damage after traumatic brain injury is therapy with stem cells or their secretion products. The secretome of mesenchymal stromal cells, containing a wide range of biologically active molecules and molecular complexes, has a unique ability to affect a wide range of pathogenetic mechanisms that occur after traumatic brain injury. Recent advances in molecular and cellular biology (in particular, obtaining cell lines with prolonged proliferative potential) open up opportunities for clinical translation of this technology. Conclusion: existing therapy for the consequences of traumatic brain injury has limited effectiveness and does not allow for the prevention of delayed damage to brain tissue. One of the most promising approaches to preventing the development of undesirable consequences of traumatic brain injury is therapy with stem cells or products of their secretion.
- 25 March 2023
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 4,p. 241-255
Transcranial magnetic stimulation for treatment-resistant depression in patients with residual-organic insufficiency of the central nervous system
This article discusses the relationship of three global topics, each of which is of particular interest in the scientific community: transcranial magnetic stimulation as a treatment method, treatment-resistant depression, and residual-organic insufficiency of the central nervous system. Depression has become one of the most common diseases in the world, affecting more than 264 million people. According to various clinical data, drug therapy is effective in about 70 % of cases. In the remaining 30 %, there is no efficiency, or it turns out to be incomplete. These conditions can be comorbid with a variety of exogenous organic symptoms. Up to 30 % of patients seeking medical help in connection with neurotic disorders have signs of residual-organic insufficiency. The treatment of these conditions requires the search for methods to resolve them. One of these methods is transcranial magnetic stimulation. It is a non-invasive and well-tolerated treatment for depression, with proven clinical efficacy.
- 25 March 2023
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 4,p. 241-255
Transcranial magnetic stimulation for treatment-resistant depression in patients with residual-organic insufficiency of the central nervous system
This article discusses the relationship of three global topics, each of which is of particular interest in the scientific community: transcranial magnetic stimulation as a treatment method, treatment-resistant depression, and residual-organic insufficiency of the central nervous system. Depression has become one of the most common diseases in the world, affecting more than 264 million people. According to various clinical data, drug therapy is effective in about 70 % of cases. In the remaining 30 %, there is no efficiency, or it turns out to be incomplete. These conditions can be comorbid with a variety of exogenous organic symptoms. Up to 30 % of patients seeking medical help in connection with neurotic disorders have signs of residual-organic insufficiency. The treatment of these conditions requires the search for methods to resolve them. One of these methods is transcranial magnetic stimulation. It is a non-invasive and well-tolerated treatment for depression, with proven clinical efficacy.